Could Regeneron Trial Deal Change The Bull Case For Biohaven (BHVN)?

• Biohaven announced a clinical supply agreement with Regeneron to test its investigational agent BHV-1530 together with cemiplimab (Libtayo) in patients with solid tumors, following earlier monotherapy and preclinical data that indicated potential synergy with Anti-PD-1 therapy.
• The new BHV-1530 and Libtayo study deepens Biohaven's broader oncology collaboration with Regeneron, building on an existing supply deal for BHV-1510 and signaling increased focus on combination approaches in difficult solid tumor settings.
• Attention now turns to how Biohaven's expanded collaboration with Regeneron around BHV-1530 and Libtayo could influence the broader investment narrative.

Scan beyond Biohaven and this Regeneron tie-up and review other oncology-focused opportunities through our curated list of 16 high quality undiscovered gems.

What Is Biohaven's Investment Narrative?

Owning Biohaven means buying into a high burn, high ambition drug developer with essentially no current product revenue and a crowded pipeline across neuroscience, immunology, and oncology. The Regeneron supply deal around BHV-1530 and Libtayo fits that story. It signals external interest in Biohaven's oncology assets and gives the team another shot on goal without adding near term commercial revenue. The share price is down over the past year and has been volatile, which already suggests the market is still treating this as a long duration story.

In the near term, the key operational questions stay the same. Can Biohaven execute across multiple Phase 2 and Phase 3 programs while running a loss of about US$586.8m, with less than one year of cash runway and no material sales today? The new combination trial increases trial complexity and capital needs, and comes on top of recent shareholder dilution and a very high P/B ratio of 164x compared with the US biotech average of 2.1x. Analyst targets and fair value models may flag upside, but the business reality is that everything still depends on data, funding, and timing lining up together.

That said, before treating Biohaven as a pure pipeline optionality story, one uncomfortable funding detail sits in the background waiting to be unpacked.

There's only one way to know the right time to buy, sell or hold Biohaven. Head to Simply Wall St's company report for the latest analysis of Biohaven's Fair Value.

Exploring Other Perspectives

One alternate lens on Biohaven treats oncology partnerships as the real catalyst. The most optimistic analysts were already modeling revenue of US$285.1m and earnings of US$49.2m by around 2029 before this Regeneron update. That is a far brighter story than consensus, and it may shift further as you explore other viewpoints.

Explore another Biohaven fair value estimate, including one that suggests as much as 425% upside from the current price.

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so consider your own analysis before making decisions.

• A great starting point for your Biohaven research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
• See our latest analysis for Biohaven. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Biohaven's overall financial health at a glance.

Looking For More Investment Ideas Beyond Biohaven?

If Biohaven has you thinking about risk, reward, and timing, it can help to widen the lens and compare it with other opportunities that match your own comfort level and goals.

• For investors who want potential upside but still care about balance sheet strength, consider using the Simply Wall St screener that surfaces a list of solid balance sheet and fundamentals (25 results) and can help you focus on sturdier businesses.
• If your priority is resilience over excitement, you might prefer a universe filtered for stability, using the screener built around 30 resilient stocks with low risk scores to keep the focus on steadier profiles.
• Those looking for underappreciated potential can scan a curated 16 high quality undiscovered gems and see how they compare to a higher risk story like Biohaven.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com